Hanmi Pharm. Co., Ltd. (KRX:128940)

Market Cap	7.52T +153.4%
Revenue (ttm)	1.47T -6.4%
Net Income	116.48B -27.5%
EPS	9,186.55 -27.5%
Shares Out	12.68M
PE Ratio	64.55
Forward PE	41.43
Dividend	1,250.00 (0.21%)
Ex-Dividend Date	n/a

Volume	122,641
Average Volume	164,056
Open	589,000
Previous Close	594,000
Day's Range	571,000 - 598,000
52-Week Range	214,500 - 647,000
Beta	0.49
RSI	61.64
Earnings Date	Feb 5, 2026

About Hanmi Pharm.

Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company’s products include Gugutams, a urological combination therapy combining two active ingredients: tamsulosin, a treatment for Obstructive Prostatic Growth (OPG), and tadalafil, a treatment for erectile dysfunction (ED). The company ha...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1973
• Employees: 2,400
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 128940

Financial Performance

In 2024, Hanmi Pharm.'s revenue was 1.50 trillion, an increase of 0.31% compared to the previous year's 1.49 trillion. Earnings were 121.32 billion, a decrease of -17.04%.